関連する実験動画
Updated: Feb 23, 2026

06:08
Formulating and Characterizing an Exosome-based Dopamine Carrier System
Published on: April 4, 2022
3.7K
血管性認知症におけるエクソソーム媒介神経保護:メカニズム,分子経路,治療展望
Farzaneh Fazli1, Samin Davoody2, Nicole Vissers3
1Neurosciences Research Center (NSRC), Tabriz University of Medical Sciences, Tabriz, Iran; Department of Anatomical Sciences, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran.
Molecular and cellular probes
|February 21, 2026
まとめ
エクソソームは,脳細胞の通信と修復を改善することによって,血管性認知症 (VaD) の治療に有望であることが示されています. 血脳障壁を横断する彼らの能力は,新しいVaD療法を開発するための重要な焦点となっています.
科学分野:
- 神経科学は神経科学である.
- 細胞生物学 細胞生物学
- バイオメディカルエンジニアリング
背景:
- 血管性認知症 (Vascular dementia, VaD) は,認知機能の低下を特徴とする一般的な神経疾患で,海馬の損傷と記憶障害に関連しています.
- エクソソーム,ナノスケールの細胞外小胞は,中枢神経系内の細胞間通信に不可欠です.
- 現在のVaD治療は主に症状によるもので,病気を修正する介入の必要性を強調しています.
研究 の 目的:
- 中枢神経系の機能におけるエクソソームの役割を検討する.
- VaD.に対するエクソソームベースの治療戦略の最近の進歩を調べる.
- エクソソーム療法の臨床翻訳における課題と将来の方向性について議論する.
主な方法:
- エクソソームとVaDに関する現在の研究に関する文献レビュー.
- シナプス性可塑性,神経炎症,アポトーシス,血管新生を含むエクソソーム機能の分析.
- エクソソームベースの治療アプローチの評価と,血脳障壁を越える可能性.
主要な成果:
- エクソソームは,生物活性分子を運ぶことで細胞間通信を促進します.
- エクソソームは,シナプス性可塑性を強化し,神経炎症を調節し,アポトーシスを抑制し,血管新生を促進することによって,ヴァーディの治療的可能性を示しています.
- エクソソームは,血液-脳障壁を横断するユニークな能力を有しており,治療薬の標的の投与を可能にします.
結論:
- エクソソームは,多面的な神経保護効果があるため,血管性認知症の有望な治療法である.
- エクソソームベースのVaD療法の臨床翻訳における課題を克服するために,さらなる研究開発が不可欠です.
- エクソソームベースの介入は,現在進行中の症状管理を超えて,ヴァーディ疾患の疾患修正治療への潜在的な経路を提供します.
関連する概念動画
Alzheimer's Disease: Treatment
1.1K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.1K
The Blood-brain Barrier
53.8K
Overview
53.8K
Overview of Exosomes
3.8K
Exosomes are stable, lipid bilayer-enclosed vesicles capable of crossing biological barriers. They can carry a wide range of molecules required for intercellular communication. Once exosomes are released from the cell where they originated, they enter a recipient cell through various pathways such as fusion, receptor-mediated endocytosis, macropinocytosis, and phagocytosis.
Stahl et al. discovered exosomes in 1983, but the exosomes were initially considered waste products released from the...
Stahl et al. discovered exosomes in 1983, but the exosomes were initially considered waste products released from the...
3.8K
Alzheimer's Disease: Overview
1.8K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.8K
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
1.0K
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
1.0K

